Clinical Trials Logo
  1. Home
  2. IBS - Irritable Bowel Syndrome
  3. NCT05995899

Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation

IBS - Irritable Bowel Syndrome Clinical Trial

Official title:
An Open-label, Single Center Investigator Sponsored Study Assessing the Effect of Tenapanor on Metagenomic and Metabolomic Markers in Patients With Irritable Bowel Syndrome With Constipation

Clinical Trial Summary

The aim of this study is to better understand how tenapanor affects the metagenomics and metabolomics of patients with irritable bowel syndrome with constipation (IBS-C). Tenapanor is the newest FDA-approved agent for IBS-C. It is a small molecule that inhibits the NHE3 receptor, leading to impaired sodium and water absorption in the intestine. Previous clinical trials comparing tenapanor to placebo showed that a 50 mg dose of tenapanor led to increased bowel movements and decreased abdominal pain. This study consists of an 8-week treatment period in which subjects will ingest one capsule of tenapanor (50 mg per dose), twice daily, and send in stool samples following 4 weeks and 8 weeks of treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05995899
Study type Interventional
Source Massachusetts General Hospital
Contact Annie Zhu
Phone 6177240480
Email azhu13@mgh.harvard.edu
Status Recruiting
Phase Phase 4
Start date February 6, 2024
Completion date November 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05118243 - Innovative Tools to Produce Legume-based Foods for Increased Consumer Acceptance N/A
Completed NCT04422327 - The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome Phase 1/Phase 2
Recruiting NCT05178017 - Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS) N/A
Completed NCT05197413 - Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms N/A
Completed NCT04905524 - Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP) N/A
Recruiting NCT06297785 - Online, Gut-directed Hypnotherapy for Patients With Irritable Bowel Syndrome (IBS) N/A
Recruiting NCT05874830 - The Optimal Route of Fecal Microbiota Transplantation for Irritable Bowel Syndrome N/A
Active, not recruiting NCT04723056 - Zemedy Application for Irritable Bowel Syndrome N/A
Completed NCT05565612 - Clinical Trial to Evaluate the Effect of a Probiotic Mixture on Signs and Symptoms of Irritable Bowel Syndrome N/A
Recruiting NCT03131414 - The IMAGINE-SPOR CIHR Chronic Disease Network
Completed NCT03333291 - Fecal Transplantation in Patients With IBS N/A
Completed NCT03449628 - L. Casei DG® in Patients With Irritable Bowel Syndrome. N/A
Recruiting NCT06215222 - Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease
Completed NCT05016596 - Postprandial Lipids in IBS and Nutritional Treatment N/A
Recruiting NCT04760353 - The Effect of a Probiotic Mixture in Obese Patients With Irritable Bowel Syndrome N/A
Recruiting NCT04217733 - Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome Phase 3
Completed NCT03178877 - The Prevalence of Irritable Bowel Syndrome Using Rome IV Criteria in Medical Student and The Related Factors N/A
Recruiting NCT05990764 - Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS) N/A
Completed NCT03948854 - Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients N/A
Completed NCT04898257 - Effect of Lactibiane Tolerance® to Treat Leaky Gut in Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)Patients N/A